Pharmacological postconditioning with sappanone A ameliorates myocardial ischemia reperfusion injury and mitochondrial dysfunction via AMPK-mediated mitochondrial quality control
- 1. Department of Cardiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou (China)
- 2. Medical Research Center, Shengjing Hospital of China Medical University, Shenyang (China)
- 3. The Central Laboratory of the First Affiliated Hospital of China Medical University, Shenyang (China)
Description
Highlights: • Sappanone A postconditioning protects against myocardial ischemia reperfusion injury. • Sappanone A postconditioning ameliorates mitochondrial dysfunction. • Sappanone A activates AMPK activity. • Sappanone A modulates mitochondrial quality control in an AMPK-dependent manner. Pharmacological postconditioning (PPC), drug intervention before or during the early minutes of reperfusion, could stimulate cardioprotection as ischemic postconditioning. In this study, we examined whether PPC with sappanone A (SA), a homoisoflavanone with potent antioxidant and anti-inflammatory activity, has a protective effect on myocardial ischemia reperfusion injury (MIRI), and explored the underlying mechanism. A MIRI model was established using the Langendorff method. After 30 min of ischemia, isolated rat hearts were treated with SA at the onset of reperfusion to stimulate PPC. The changes in myocardial infarct size, mitochondrial function, mitochondrial biogenesis, mitophagy, and mitochondrial fission and fusion were detected. The results showed that SA postconditioning decreased the myocardial infarct size, inhibited the release of lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), and cardiac troponin (cTnI), as well as improved cardiac function, enhanced myocardial ATP content and mitochondrial complex activity, and prevented the loss of mitochondrial membrane potential and opening of mitochondrial permeability transition pore (mPTP). Mechanistically, we found that SA was an AMP-activated protein kinase (AMPK) activator, and SA postconditioning could facilitate mitochondrial biogenesis by increasing mitochondrial DNA (mtDNA) copy number and the expression of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α). In addition, it balanced mitochondrial dynamics by decreasing fission and increasing fusion, and enhanced mitophagy in an AMPK-dependent manner. Moreover, AMPK silencing abolished the cardioprotection of SA postconditioning. Collectively, our study demonstrated that SA postconditioning ameliorated MIRI and mitochondrial dysfunction by regulation of mitochondrial quality control via activating AMPK. This finding provides a new insight into pharmacological action and clinical use of SA.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.taap.2021.115668Additional details
Identifiers
- DOI
- 10.1016/j.taap.2021.115668;
- PII
- S0041008X21002726;
Publishing Information
- Journal Title
- Toxicology and Applied Pharmacology
- Journal Volume
- 427
- Journal Page Range
- vp.
- ISSN
- 0041-008X
- CODEN
- TXAPA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 54051843
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ANTIOXIDANTS; CREATINE; DNA; DRUGS; HEART; INFLAMMATION; INJURIES; ISCHEMIA; LACTATE DEHYDROGENASE; LACTATES; MITOCHONDRIA; PERMEABILITY; PHOSPHOTRANSFERASES; QUALITY CONTROL; RATS; RECEPTORS
- Descriptors DEC
- AMINO ACIDS; ANEMIAS; ANIMALS; BODY; CARBOXYLIC ACID SALTS; CARBOXYLIC ACIDS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL CONSTITUENTS; CONTROL; DISEASES; ENZYMES; HEMIACETAL DEHYDROGENASES; HEMIC DISEASES; MAMMALS; MEMBRANE PROTEINS; NUCLEIC ACIDS; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANS; OXIDOREDUCTASES; PATHOLOGICAL CHANGES; PHOSPHORUS-GROUP TRANSFERASES; PHYSICAL PROPERTIES; PROTEINS; RODENTS; SYMPTOMS; TRANSFERASES; VASCULAR DISEASES; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2021 Elsevier Inc. All rights reserved.